Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Rodriguez-Ruiz ME"'
Autor:
Alcibar, OL, Candini, D, Lopez-Campos, F, Antequera, MA, Macias, VM, Conde, AJ, Perez, AR, Moron, AH, Martinez, JC, Albiach, CF, Aguilar, SN, Rodriguez-Ruiz, ME
Publikováno v:
CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Harnessing the patient's own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical checkpoints that control the activation of T cells, the immune cells able to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::63e70839ee80f8fe2685dfc1f3741dc2
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10660
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10660
Autor:
Rodriguez-Ruiz, ME, Rodriguez, I, Leaman, O, Lopez-Campos, F, Montero, A, Conde, AJ, Aristu, JJ, Lara, P, Calvo, FM, Melero, I
Publikováno v:
PHARMACOLOGY & THERAPEUTICS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Radiotherapy of cancer has been traditionally considered as a local therapy without noticeable effects outside the irradiated fields. However, ionizing radiation exerts multiple biological effects on both malignant and stromal cells that account for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::45e7a2f8b8a3d67aaf6da62327adcc9d
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10100
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10100
Autor:
Perez-Gracia, JL, Sanmamed, MF, Bosch, A, Patino-Garcia, A, Schalper, KA, Segura, V, Bellmunt, J, Tabernero, J, Sweeney, CJ, Choueiri, TK, Martin, M, Fusco, JP, Rodriguez-Ruiz, ME, Calvo, A, Prior, C, Paz-Ares, L, Pio, R, Gonzalez-Billalabeitia, E, Hernandez, AG, Paez, D, Piulats, JM, Gurpide, A, Andueza, M, de Velasco, G, Pazo, R, Grande, E, Nicolas, P, Abad-Santos, F, Garcia-Donas, J, Castellano, D, Pajares, MJ, Suarez, C, Colomer, R, Montuenga, LM, Melero, I
Publikováno v:
CANCER TREATMENT REVIEWS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bba5564c7b4868c57c5f7e2df3995fcb
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6683
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6683
Autor:
Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Garasa S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Ochoa MC; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Sanchez-Gregorio S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Gomis G; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Martinez-Monge R; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Pinci B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Valencia K; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Solid Tumors Program, Center for Applied Medical Research (CIMA), Pamplona, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Barbés B; Department of Radiation Physics and Radiation Protection, Clínica Universidad de Navarra, Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Azpilikueta A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., García-Cardosa M; Department of Physics and Applied Mathematics, Universidad de Navarra, Pamplona, Spain., Burguete J; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Physics and Applied Mathematics, Universidad de Navarra, Pamplona, Spain., Eguren-Santamaría I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Medical Oncology, Universidad de Navarra, Pamplona, Spain., Garate-Soraluze E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Perez-Gracia JL; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Medical Oncology, Universidad de Navarra, Pamplona, Spain., de Andrea CE; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Anatomy, Physiology and Pathology, Universidad de Navarra, Pamplona, Spain., Rodriguez-Ruiz ME; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 13; Vol. 30 (18), pp. 4131-4142.
Autor:
de Dios O; Neurooncology Unit, Chronic Disease Deparment (UFIEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Ramírez-González MA; Neurooncology Unit, Chronic Disease Deparment (UFIEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Gómez-Soria I; Neurooncology Unit, Chronic Disease Deparment (UFIEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Segura-Collar B; Neurooncology Unit, Instituto de Investigaciones Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain.; Department of Anatomical Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain., Manosalva J; Advanced Microscopy Unit, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Megías D; Advanced Microscopy Unit, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., De Andrea CE; Department of Anatomy, Physiology and Pathology, Universidad de Navarra, Pamplona, Navarra, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Fernández-Rubio L; Division of Immunology and Immunotherapy, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Navarra, Spain., Hernández-Laín A; Neurooncology Unit, Instituto de Investigaciones Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain.; Department of Neuropathology, Hospital Universitario 12 de Octubre, Madrid, Spain., Sepúlveda-Sánchez JM; Neurooncology Unit, Instituto de Investigaciones Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain.; Hospital HM Sanchinarro, Centro Integral Oncologico Clara Campal, Madrid, Spain., Rodriguez-Ruiz ME; Division of Immunology and Immunotherapy, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Navarra, Spain.; Department of Radiation Oncology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain., Pérez-Núñez Á; Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain.; Department of Surgery, Universidad Complutense de Madrid, Facultad de Medicina, Madrid, Spain., Wainwright DA; Department of Neurological Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA.; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA., Gargini R; Neurooncology Unit, Instituto de Investigaciones Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain ricgargini.imas12@h12o.es psanchezg@isciii.es.; Department of Anatomical Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain., Sánchez-Gómez P; Neurooncology Unit, Chronic Disease Deparment (UFIEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain ricgargini.imas12@h12o.es psanchezg@isciii.es.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Aug 30; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 30.
Autor:
Segal NH; Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weill Cornell Medical College, New York, NY, USA. segaln@mskcc.org., Melero I; Clínica Universidad de Navarra and CIMA University of Navarra, Navarra, Spain.; CIBERONC, Instituto de Salud Carlso III, Madrid, Spain., Moreno V; Hospital Fundación Jiménez Díaz, Madrid, Spain., Steeghs N; Netherlands Cancer Institute, Amsterdam, Netherlands., Marabelle A; Gustave Roussy, Université Paris-Saclay, Villejuif, France., Rohrberg K; Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark., Rodriguez-Ruiz ME; Clínica Universidad de Navarra and CIMA University of Navarra, Navarra, Spain., Eder JP; Yale University Cancer Center, New Haven, CT, USA., Eng C; Vanderbilt Ingram Cancer Center, Nashville, TN, USA., Manji GA; Columbia University, New York, NY, USA., Waterkamp D; Genentech, Inc., South San Francisco, CA, USA., Leutgeb B; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Bouseida S; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Flinn N; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Das Thakur M; Genentech, Inc., South San Francisco, CA, USA., Elze MC; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Koeppen H; Genentech, Inc., South San Francisco, CA, USA., Jamois C; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Martin-Facklam M; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Lieu CH; University of Colorado, Aurora, Denver, CO, USA., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Paz-Ares L; University Hospital 12 de Octubre, Madrid, Spain., Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain., Argilés G; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain.; Departament de Cirurgia, Universitat Autònoma de Barcelona, Barcelona, Spain.
Publikováno v:
Nature communications [Nat Commun] 2024 May 15; Vol. 15 (1), pp. 4091. Date of Electronic Publication: 2024 May 15.
Autor:
Levy A; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France. antonin.levy@gustaveroussy.fr.; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France. antonin.levy@gustaveroussy.fr.; Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France. antonin.levy@gustaveroussy.fr., Morel D; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France.; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France., Texier M; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France.; Oncostat 1018 INSERM, University Paris-Saclay, Villejuif, France., Sun R; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France.; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France.; Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France., Durand-Labrunie J; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France., Rodriguez-Ruiz ME; Department of Radiation Oncology, Clínica Universidad de Navarrra, Pamplona, Spain., Racadot S; Department of Radiation Oncology, Centre Léon Bérard, Lyon, France., Supiot S; Department of Radiation Oncology, Institut de Cancérologie de L'Ouest-Centre Rene Gauducheau, St Herblain, Nantes, France., Magné N; Department of Radiation Oncology, Institut Bergonié, Bordeaux, France., Cyrille S; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France.; Oncostat 1018 INSERM, University Paris-Saclay, Villejuif, France., Louvel G; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France., Massard C; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France.; Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France.; Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France., Verlingue L; Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France., Bouquet F; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland., Bustillos A; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland., Bouarroudj L; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France.; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France.; Bioinformatic Platform, Gustave Roussy, Villejuif, France., Quevrin C; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France., Clémenson C; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France., Mondini M; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France., Meziani L; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France., Tselikas L; Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France.; Department of Interventional Radiology, Gustave Roussy, Villejuif, France., Bahleda R; Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France., Hollebecque A; Drug Development Department (DITEP), Gustave Roussy-Cancer Campus, Villejuif, France., Deutsch E; Department of Radiation Oncology, Gustave Roussy, 114 Rue E. Vaillant, 94850, Villejuif, France. eric.deutsch@gustaveroussy.fr.; INSERM U1030, Radiothérapie Moléculaire, Villejuif, France. eric.deutsch@gustaveroussy.fr.; Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France. eric.deutsch@gustaveroussy.fr.
Publikováno v:
Molecular cancer [Mol Cancer] 2024 Mar 23; Vol. 23 (1), pp. 61. Date of Electronic Publication: 2024 Mar 23.
Autor:
Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Gomis G; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Manzanal A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Martinez Riaño A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Rodriguez Ruiz ME; Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Pharmacy, University 'G. D'Annunzio' Chieti-Pescara, Chieti, Italy.
Publikováno v:
Immunological reviews [Immunol Rev] 2024 Jan; Vol. 321 (1), pp. 143-151. Date of Electronic Publication: 2023 Oct 11.
Autor:
Alvarez M; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Molina C; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Garasa S; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Ochoa MC; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Rodriguez-Ruiz ME; Departments of Immunology and Oncology (CCUN), Clínica Universidad de Navarra, Pamplona, Spain., Gomis G; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Cirella A; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Olivera I; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Glez-Vaz J; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Gonzalez-Gomariz J; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Luri-Rey C; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Azpilikueta A; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Bolaños E; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Teijeira A; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Berraondo P; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Quintero M; Highlight Therapeutics, Valencia, Spain., Melero I; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Departments of Immunology and Oncology (CCUN), Clínica Universidad de Navarra, Pamplona, Spain.; Nuffield Department of Medicine and Oxford Center for Immuno-Oncology, University of Oxford, Oxford, UK.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2023 Apr 05; Vol. 12 (1), pp. 2197370. Date of Electronic Publication: 2023 Apr 05 (Print Publication: 2023).
Autor:
Labiano S; Department of Pediatrics, University Clinic of Navarra, Pamplona, Spain., Serrano-Mendioroz I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain., Rodriguez-Ruiz ME; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain; Departments of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: mrruiz@unav.es.
Publikováno v:
Methods in cell biology [Methods Cell Biol] 2023; Vol. 174, pp. 1-16. Date of Electronic Publication: 2022 Aug 18.